

SEQUENCE LISTING

<110> TRANSLATIONAL CANCER DRUGS PHARMA, S.L.

<120> METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

<130> P4096PC00

<150> EP08380270.2

<151> 2008-09-17

<160> 7

<170> PatentIn version 3.5

<210> 1

<211> 1188

<212> DNA

<213> Human

<400> 1

atggcgggccg aggcgacagc tgtggccgga agcggggctg ttggcggtg cctggccaaa	60
gacggcttgc agcagtctaa gtgcccggac actaccccaa aacggcggtg cgccctcgctg	120
ctgtcgctg acgccgagcg ccgagcctac caatggtgcc gggagtactt gggcgggggcc	180
tggcgccgag tgcagcccga ggagctgagg gtttaccctg tgagcgagg cctcagcaac	240
ctgctcttcc gctgctcgct cccggaccac ctgcccagcg ttggcgagga gcccggggag	300
gtgcttctgc ggctgtacgg agccatcttg cagggcgtgg actccctggt gctagaaagc	360
gtgatgttcg ccatacttgc ggagcggctg ctggggcccc agctgtacgg agtcttccca	420
gagggccggc tggaacagta catcccaagt cggccattga aaactcaaga gcttcgagag	480
ccagtgttgt cagcagccat tgccacgaag atggcgcaat ttcattggcat ggagatgcct	540
ttcaccaagg agccccactg gctgtttggg accatggagc ggtacctaaa acagatccag	600
gacctgcccc caactggcct ccctgagatg aacctgctgg agatgtacag cctgaaggat	660
gagatgggca acctcaggaa gttactagag tctaccccat cgccagtcgt cttctgccac	720
aatgacatcc aggaaggga catcttgctg ctctcagagc cagaaaatgc tgacagcctc	780
atgctggtgg acttcagata cagcagttat aactataggg gctttgacat tgggaacct	840
ttttgtgagt gggtttatga ttatactcac gaggaatggc ctttctacaa agcaaggccc	900
acagactacc cactcaaga acagcagttg cattttattc gtcattacct ggcagaggca	960
aagaaagggtg agaccctctc ccaagaggag cagagaaaac tggaagaaga tttgctggta	1020
gaagtcagtc ggtatgctct ggcatcccat ttcttctggg gtctgtggtc catcctccag	1080
gcatccatgt ccaccataga atttggttac ttggactatg ccagtcctcg gttccagttc	1140
tacttccagc agaaggggca gctgaccagt gtccactcct catcctag	1188

<210> 2
 <211> 395
 <212> PRT
 <213> Human

<400> 2

Met Ala Ala Glu Ala Thr Ala Val Ala Gly Ser Gly Ala Val Gly Gly
 1 5 10 15

Cys Leu Ala Lys Asp Gly Leu Gln Gln Ser Lys Cys Pro Asp Thr Thr
 20 25 30

Pro Lys Arg Arg Arg Ala Ser Ser Leu Ser Arg Asp Ala Glu Arg Arg
 35 40 45

Ala Tyr Gln Trp Cys Arg Glu Tyr Leu Gly Gly Ala Trp Arg Arg Val
 50 55 60

Gln Pro Glu Glu Leu Arg Val Tyr Pro Val Ser Gly Gly Leu Ser Asn
 65 70 75 80

Leu Leu Phe Arg Cys Ser Leu Pro Asp His Leu Pro Ser Val Gly Glu
 85 90 95

Glu Pro Arg Glu Val Leu Leu Arg Leu Tyr Gly Ala Ile Leu Gln Gly
 100 105 110

Val Asp Ser Leu Val Leu Glu Ser Val Met Phe Ala Ile Leu Ala Glu
 115 120 125

Arg Ser Leu Gly Pro Gln Leu Tyr Gly Val Phe Pro Glu Gly Arg Leu
 130 135 140

Glu Gln Tyr Ile Pro Ser Arg Pro Leu Lys Thr Gln Glu Leu Arg Glu
 145 150 155 160

Pro Val Leu Ser Ala Ala Ile Ala Thr Lys Met Ala Gln Phe His Gly
 165 170 175

Met Glu Met Pro Phe Thr Lys Glu Pro His Trp Leu Phe Gly Thr Met
 180 185 190

Glu Arg Tyr Leu Lys Gln Ile Gln Asp Leu Pro Pro Thr Gly Leu Pro
 195 200 205

Glu Met Asn Leu Leu Glu Met Tyr Ser Leu Lys Asp Glu Met Gly Asn
 210 215 220

Leu Arg Lys Leu Leu Glu Ser Thr Pro Ser Pro Val Val Phe Cys His
 225 230 235 240

Asn Asp Ile Gln Glu Gly Asn Ile Leu Leu Leu Ser Glu Pro Glu Asn
 245 250 255

Ala Asp Ser Leu Met Leu Val Asp Phe Glu Tyr Ser Ser Tyr Asn Tyr
 260 265 270

Arg Gly Phe Asp Ile Gly Asn His Phe Cys Glu Trp Val Tyr Asp Tyr
 275 280 285

Thr His Glu Glu Trp Pro Phe Tyr Lys Ala Arg Pro Thr Asp Tyr Pro
 290 295 300

Thr Gln Glu Gln Gln Leu His Phe Ile Arg His Tyr Leu Ala Glu Ala
 305 310 315 320

Lys Lys Gly Glu Thr Leu Ser Gln Glu Glu Gln Arg Lys Leu Glu Glu
 325 330 335

Asp Leu Leu Val Glu Val Ser Arg Tyr Ala Leu Ala Ser His Phe Phe
 340 345 350

Trp Gly Leu Trp Ser Ile Leu Gln Ala Ser Met Ser Thr Ile Glu Phe
 355 360 365

Gly Tyr Leu Asp Tyr Ala Gln Ser Arg Phe Gln Phe Tyr Phe Gln Gln
 370 375 380

Lys Gly Gln Leu Thr Ser Val His Ser Ser Ser
 385 390 395

<210> 3
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> Sequence of a shRNA specific for ChoK alpha

<400> 3
 aactgatgct cattgatttc g

<210> 4

<211> 19
 <212> RNA
 <213> Artificial

<220>
 <223> siRNA specific for choline kinase

<400> 4
 caugcuguuc cagugcucc 19

<210> 5
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> siRNA specific for acid ceramidase as described in Morales et al
 (Oncogene, 2007, 26:905-916)

<400> 5
 aaaatcaacc tadcctcctt c 21

<210> 6
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> siRNA specific for acid ceramidase as described in W02007136635

<400> 6
 aatcaaccta tcctccttca g 21

<210> 7
 <211> 281
 <212> PRT
 <213> Human

<400> 7

Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys
 1 5 10 15

Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala
 20 25 30

Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys
 35 40 45

Tyr Ser Lys Ser Gly Ile Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr
 50 55 60

Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val
 65 70 75 80

Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser
85 90 95

Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro
100 105 110

Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly
115 120 125

Thr Arg Gly Arg Ser Asn Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu
130 135 140

Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly
145 150 155 160

His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile
165 170 175

His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe
180 185 190

Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln
195 200 205

Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys
210 215 220

Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr
225 230 235 240

Ser Ile Tyr Gln Gly Gly Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile
245 250 255

Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala
260 265 270

Ser Phe Phe Gly Ala Phe Leu Val Gly
275 280